Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Saisei Pharma Co. Ltd. manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners across 2 distinct art units. This distribution indicates that the company's pharmaceutical research spans different specialized examination categories. The 2 pending office actions are the only matters currently active in the company's portfolio.
The busiest examiner, CHEN, CATHERYNE, is responsible for 1 pending office action. Since there are 2 pending office actions in total, the workload is divided between the 2 distinct examiners. Each of the 2 distinct examiners is reviewing an application in a separate art unit within the Biotechnology & Pharmaceuticals field.
The involvement of 2 distinct art units for 2 pending office actions suggests a diverse technical focus within the Biotechnology & Pharmaceuticals field. Practitioners must manage the prosecution according to the specific standards of these 2 different art units. With 2 distinct examiners involved, the company must ensure that its prosecution strategy remains consistent across both pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, CATHERYNE | 1 | 37.4% | +18.0% |
| BOWLES, DAVID PAUL | 1 | 72.7% | +22.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256628 | MACROPHAGE ACTIVATOR | BOWLES, DAVID PAUL | 45d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256628 | MACROPHAGE ACTIVATOR | BOWLES, DAVID PAUL | 45d overdue |
| 18619519 | INFLAMMATORY CYTOKINE PRODUCTION INHIBITOR | CHEN, CATHERYNE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18619519 | INFLAMMATORY CYTOKINE PRODUCTION INHIBITOR | CHEN, CATHERYNE | 1655 | §102 | Final Rejection | — | Pending | Mar 28, 2024 |
| 18256628 | MACROPHAGE ACTIVATOR | BOWLES, DAVID PAUL | 1654 | §103§112 | Final Rejection | 45d overdue | Pending | Jun 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial